Article
The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Oncotarget - 10 Jan 2017
Eliade Marie, Skrzypski Jeremy, Baurand Amandine, Jacquot Caroline, Bertolone Geoffrey, Loustalot Catherine, Coutant Charles, Guy France, Fumoleau Pierre, Duffourd Yannis, Arnould Laurent, Delignette Alexandra, Padéano Marie-Martine, Lepage Côme, Raichon-Patru Géraldine, Boudrant Axelle, Bône-Lépinoy Marie-Christine, Villing Anne-Laure, Charpin Aurélie, Peignaux Karine, Chevrier Sandy, Vegran Frédérique, Ghiringhelli François, Boidot Romain, Sevenet Nicolas, Lizard Sarab, Faivre Laurence
Abstract excerpt
Until recently, the molecular diagnosis of hereditary breast and ovarian cancer (HBOC) was mostly based on BRCA1/2 testing. Next generation sequencing and the recent discovery of new genes involved in HBOC now permit the transfer of genomic capture targeting multiple candidate genes from research to clinical use. However, the implications for the management of patients and their families have not been extensively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.